China Pharma Holding (China Pharma Holding) Cash-to-Debt : 0.31 (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is China Pharma Holding Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. China Pharma Holding's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.31.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, China Pharma Holding couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for China Pharma Holding's Cash-to-Debt or its related term are showing as below:

CPHI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: 0.24 Max: 0.39
Current: 0.31

During the past 13 years, China Pharma Holding's highest Cash to Debt Ratio was 0.39. The lowest was 0.13. And the median was 0.24.

CPHI's Cash-to-Debt is ranked worse than
68.61% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.945 vs CPHI: 0.31

China Pharma Holding Cash-to-Debt Historical Data

The historical data trend for China Pharma Holding's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

China Pharma Holding Cash-to-Debt Chart

China Pharma Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.16

0.13

0.39

0.23

0.31

China Pharma Holding Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.23	0.14	0.12	0.25	0.31

Competitive Comparison of China Pharma Holding's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Pharma Holding's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where China Pharma Holding's Cash-to-Debt falls into.

China Pharma Holding Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

China Pharma Holding's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.424	/	(3.182	+	1.452)
	=	0.31

China Pharma Holding's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.424	/	(3.182	+	1.452)
	=	0.31

China Pharma Holding (OTCPK:CPHI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

China Pharma Holding Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

China Pharma Holding (China Pharma Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (OTCPK:CPHI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216

Website

https://www.chinapharmaholdings.com

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

Executives

Ke Deng	10 percent owner	NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216
Frank Waung	officer: Chief Financial Officer	72 GREAT HILLS RD., SHORT HILLS NJ 07078
G Michael Bennett	director	4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600
Yingwen Zhang	director	NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041
Baowen Dong	director	NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041
Heung Mei Tsui	director, 10 percent owner	FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX
Zhilin Li	officer: President and CEO	2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216
Jian Yang	officer: Secretary	NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216
Xinhua Wu	officer: CFO	2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216
George L Diamond	10 percent owner	174 FM 1830, ARGYLE TX 76226
David F Brigante	10 percent owner	174FM 1830, ARGYLE TX 76226
Marat Rosenberg	10 percent owner	17 FM 1830, ARGYLE TX 76226
Halter Financial Investments Lp	10 percent owner	174 FM 1830, ARGYLE TX 76226
Halter Financial Investments Gp Llc	10 percent owner	174 FM 1830, ARGYLE TX 76226
Timothy P Halter	director, 10 percent owner, officer: CEO, President & CFO	174 FM 1830, ARGYLE TX 76226